Developers
Sanaz Gidfar, Farnoud Y. Milani, Behrad Y. Milani, Hossein Sagha, Ali R. Djalilian, etc.
Description of the technology
Rapamycin has previously been shown to have
Cell growth and viability were evaluated by bright field microscopy. Cell proliferation and cycle were evaluated by flow cytometry. The expression of differentiation markers was evaluated by quantitative PCR and Western blot. Senescence was evaluated by
The results demonstrated that primary human corneal epithelial cells treated with rapamycin had lower proliferation but considerably longer survival in vitro.
Practical application
Rapamycin treatment in accordance with this technology allows to prevent replicative senescence (Hayflick limit) in culture of primary corneal epithelial cells. It is crucial for both researches of processes of ageing (particularly, cell senescence) and practical application of cell therapies and transplantology (for example, maintenance of viability of primary corneal epithelial cells in vitro for corneal transplantation).
Laboratories
- Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago (USA)
Links
http://www.nature.com/articles/srep40308Publications
- Gidfar, S. et al. «Rapamycin Prolongs the Survival of Corneal Epithelial Cells in Culture." 7 Scientific Reports, (2017): 40308.
- Milani, B. Y. et al. Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 54(12), 7424–7430 (2013).